Literature DB >> 30345907

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Pierre-Antoine Juge1, Joyce S Lee1, Esther Ebstein1, Hiroshi Furukawa1, Evgenia Dobrinskikh1, Steven Gazal1, Caroline Kannengiesser1, Sébastien Ottaviani1, Shomi Oka1, Shigeto Tohma1, Naoyuki Tsuchiya1, Jorge Rojas-Serrano1, Montserrat I González-Pérez1, Mayra Mejía1, Ivette Buendía-Roldán1, Ramcés Falfán-Valencia1, Enrique Ambrocio-Ortiz1, Effrosyni Manali1, Spyros A Papiris1, Theofanis Karageorgas1, Dimitrios Boumpas1, Katarina Antoniou1, Coline H M van Moorsel1, Joanne van der Vis1, Yaël A de Man1, Jan C Grutters1, Yaping Wang1, Raphaël Borie1, Lidwine Wemeau-Stervinou1, Benoît Wallaert1, René-Marc Flipo1, Hilario Nunes1, Dominique Valeyre1, Nathalie Saidenberg-Kermanac'h1, Marie-Christophe Boissier1, Sylvain Marchand-Adam1, Aline Frazier1, Pascal Richette1, Yannick Allanore1, Jean Sibilia1, Claire Dromer1, Christophe Richez1, Thierry Schaeverbeke1, Huguette Lioté1, Gabriel Thabut1, Nadia Nathan1, Serge Amselem1, Martin Soubrier1, Vincent Cottin1, Annick Clément1, Kevin Deane1, Avram D Walts1, Tasha Fingerlin1, Aryeh Fischer1, Jay H Ryu1, Eric L Matteson1, Timothy B Niewold1, Deborah Assayag1, Andrew Gross1, Paul Wolters1, Marvin I Schwarz1, Michael Holers1, Joshua J Solomon1, Tracy Doyle1, Ivan O Rosas1, Cornelis Blauwendraat1, Mike A Nalls1, Marie-Pierre Debray1, Catherine Boileau1, Bruno Crestani1, David A Schwartz1, Philippe Dieudé1.   

Abstract

BACKGROUND: Given the phenotypic similarities between rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that the strongest risk factor for the development of idiopathic pulmonary fibrosis, the gain-of-function MUC5B promoter variant rs35705950, would also contribute to the risk of ILD among patients with RA.
METHODS: Using a discovery population and multiple validation populations, we tested the association of the MUC5B promoter variant rs35705950 in 620 patients with RA-ILD, 614 patients with RA without ILD, and 5448 unaffected controls.
RESULTS: Analysis of the discovery population revealed an association of the minor allele of the MUC5B promoter variant with RA-ILD when patients with RA-ILD were compared with unaffected controls (adjusted odds ratio, 3.8; 95% confidence interval [CI], 2.8 to 5.2; P=9.7×10-17). The MUC5B promoter variant was also significantly overrepresented among patients with RA-ILD, as compared with unaffected controls, in an analysis of the multiethnic case series (adjusted odds ratio, 5.5; 95% CI, 4.2 to 7.3; P=4.7×10-35) and in a combined analysis of the discovery population and the multiethnic case series (adjusted odds ratio, 4.7; 95% CI, 3.9 to 5.8; P=1.3×10-49). In addition, the MUC5B promoter variant was associated with an increased risk of ILD among patients with RA (adjusted odds ratio in combined analysis, 3.1; 95% CI, 1.8 to 5.4; P=7.4×10-5), particularly among those with evidence of usual interstitial pneumonia on high-resolution computed tomography (adjusted odds ratio in combined analysis, 6.1; 95% CI, 2.9 to 13.1; P=2.5×10-6). However, no significant association with the MUC5B promoter variant was observed for the diagnosis of RA alone.
CONCLUSIONS: We found that the MUC5B promoter variant was associated with RA-ILD and more specifically associated with evidence of usual interstitial pneumonia on imaging. (Funded by Société Française de Rhumatologie and others.).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30345907      PMCID: PMC6371965          DOI: 10.1056/NEJMoa1801562

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  42 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Authors:  Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2010-06

4.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

5.  Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

Authors:  E J Kim; B M Elicker; F Maldonado; W R Webb; J H Ryu; J H Van Uden; J S Lee; T E King; H R Collard
Journal:  Eur Respir J       Date:  2009-12-08       Impact factor: 16.671

6.  Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort.

Authors:  Gouri Koduri; Sam Norton; Adam Young; Nigel Cox; Paul Davies; Joe Devlin; Josh Dixey; Andrew Gough; Peter Prouse; John Winfield; Peter Williams
Journal:  Rheumatology (Oxford)       Date:  2010-03-11       Impact factor: 7.580

7.  Rheumatoid arthritis-interstitial lung disease-associated mortality.

Authors:  Amy L Olson; Jeffrey J Swigris; David B Sprunger; Aryeh Fischer; Evans R Fernandez-Perez; Josh Solomon; James Murphy; Marc Cohen; Ganesh Raghu; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2010-09-17       Impact factor: 21.405

8.  A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Imre Noth; Joe G N Garcia; Naftali Kaminski
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

9.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

Review 10.  Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.

Authors:  Eunice J Kim; Harold R Collard; Talmadge E King
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

View more
  84 in total

Review 1.  Is Progression of Pulmonary Fibrosis due to Ventilation-induced Lung Injury?

Authors:  Richard K Albert; Bradford Smith; Carrie E Perlman; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

2.  Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures.

Authors:  Haruhiko Furusawa; Jonathan H Cardwell; Tsukasa Okamoto; Avram D Walts; Iain R Konigsberg; Jonathan S Kurche; Tami J Bang; Marvin I Schwarz; Kevin K Brown; Jonathan A Kropski; Mauricio Rojas; Carlyne D Cool; Joyce S Lee; Paul J Wolters; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

3.  Telomere length and genetic variant associations with interstitial lung disease progression and survival.

Authors:  Chad A Newton; Justin M Oldham; Brett Ley; Vikram Anand; Ayodeji Adegunsoye; Gabrielle Liu; Kiran Batra; Jose Torrealba; Julia Kozlitina; Craig Glazer; Mary E Strek; Paul J Wolters; Imre Noth; Christine Kim Garcia
Journal:  Eur Respir J       Date:  2019-04-11       Impact factor: 16.671

4.  Differentially expressed lncRNAs in peripheral blood mononuclear cells from middle-aged female patients with rheumatoid arthritis-associated interstitial lung disease.

Authors:  Wei Zhou; Juan Zheng; Min Yuan; Lindong Yuan; Xiaodong Jia; Huaxiang Liu
Journal:  Clin Rheumatol       Date:  2020-03-05       Impact factor: 2.980

Review 5.  Molecular approach to the classification of chronic fibrosing lung disease-there and back again.

Authors:  Stijn E Verleden; Peter Braubach; Mark Kuehnel; Nicolas Dickgreber; Emily Brouwer; Pauline Tittmann; Florian Laenger; Danny Jonigk
Journal:  Virchows Arch       Date:  2020-11-09       Impact factor: 4.064

Review 6.  Obstructive lung diseases and risk of rheumatoid arthritis.

Authors:  H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks
Journal:  Expert Rev Clin Immunol       Date:  2020-01-06       Impact factor: 4.473

7.  The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops.

Authors:  Ashley R Rackow; David J Nagel; Claire McCarthy; Jennifer Judge; Shannon Lacy; Margaret A T Freeberg; Thomas H Thatcher; R Matthew Kottmann; Patricia J Sime
Journal:  Eur Respir J       Date:  2020-11-26       Impact factor: 16.671

Review 8.  The impact of lung microbiota dysbiosis on inflammation.

Authors:  Daping Yang; Yingying Xing; Xinyang Song; Youcun Qian
Journal:  Immunology       Date:  2019-11-11       Impact factor: 7.397

9.  The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Michael D Roth; Ning Li; Julio Charles; Maureen Mayes; Grace Kim; Jonathan Goldin; Lila Pourzand; Philip J Clements; Daniel E Furst; Dinesh Khanna; Robert M Elashoff; Shervin Assassi
Journal:  Semin Arthritis Rheum       Date:  2020-06-16       Impact factor: 5.532

Review 10.  Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Authors:  Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi
Journal:  Curr Rheumatol Rev       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.